<DOC>
	<DOCNO>NCT02951780</DOCNO>
	<brief_summary>The purpose study determine body handle LY3185643 rGlucagon effect LY3185643 rGlucagon body . This study also help determine LY3185643 safe well-tolerated . This study last least 35 day , include screening .</brief_summary>
	<brief_title>A Study LY3185643 rGlucagon Healthy Participants</brief_title>
	<detailed_description />
	<criteria>Are overtly healthy determine medical history physical examination Body mass index 18.0 30.0 kilogram per square meter ( kg/m² ) Have participate , within last 30 day , clinical trial involve investigational product Known allergy LY3185643 rGlucagon , related compound , component formulation History electrocardiogram ( ECG ) evidence heart block , abnormality 12lead ECG Abnormal blood pressure History recur symptomatic postural hypotension irrespective decrease blood pressure , asymptomatic postural hypotension screening define decrease systolic blood pressure great equal ( ≥ ) 20 millimeter Mercury ( mm Hg ) within 3 minute change supine stand position History vasovagal response faint History current cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take investigational product ; interfere interpretation data History of/current insulinoma and/or pheochromocytoma Have use systemic glucocorticoid within 3 month entry study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>